Related Experiment Video

Updated: Aug 14, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease

Yuri Sheikine1, Charlotte Sahlberg Bang, Lennart Nilsson

  • 1Experimental Cardiovascular Research Unit, Center for Molecular Medicine, L8:03, S-17176, Karolinska University Hospital, Stockholm, Sweden. yuri.sheikine@cmm.ki.se

Atherosclerosis
|December 28, 2005
PubMed

Insights

Plasma CXCL16 levels are lower in coronary artery disease (CAD) patients, suggesting a potential atheroprotective role for this chemokine in atherosclerosis development.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Biochemistry

Background:

  • The chemokine/scavenger receptor CXCL16/SR-PSOX is implicated in atherosclerosis and coronary artery disease (CAD).
  • Understanding CXCL16's role in CAD pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

  • To determine if plasma CXCL16 concentrations differ in patients with coronary artery disease (CAD).
  • To investigate the relationship between CXCL16 levels and CAD severity.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma CXCL16 levels.
  • Study included patients with stable angina pectoris (SAP), unstable angina pectoris/non-ST-elevation myocardial infarction (UAP/non-STEMI), and myocardial infarction (MI) survivors, compared to healthy controls.
  • Coronary angiography and biochemical markers were assessed in post-MI patients.

Main Results:

  • Significantly lower CXCL16 levels were observed in SAP patients compared to controls (P=0.0012).
  • A trend towards lower CXCL16 levels was noted in UAP/non-STEMI and post-MI patients compared to controls.
  • No significant correlations were found between CXCL16 levels and CAD severity, inflammatory markers, or lipid profiles.

Conclusions:

  • Lower plasma CXCL16 concentration is associated with coronary artery disease (CAD).
  • These findings suggest a potential atheroprotective function of CXCL16 in the context of CAD.
Abstract

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...